Sandra Leung, one of the longest-serving legal chiefs in the pharmaceutical industry, plans to retire from Bristol Myers Squibb in 2025 ... roles in oncology and commercial legal and compliance.

Bristol-Myers Squibb Company (NYSE ... “We have seen strong sales growth across numerous commercial products including Reblozyl, Breyanzi, and Opdualag that we look to continue into 2025.” ...

With the U.S. still mired in an overdose crisis that’s killed hundreds of thousands of people, Vertex is positioning its medicine as a valuable alternative to opioid-based therapies. Doctors say ...

Bristol-Myers Squibb has become the latest drugmaker in ... who source Eliquis only after they have bought the drug at normal commercial prices. In court documents, BMS' counsel asserts that ...

Head of R&D for Bristol Myers Squibb in Japan – he brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies. End of ...

He also made strides in curbing the opioid epidemic, granting funding to institutions ... the growth rate of the oral anticoagulant market. In partnership with Bristol Myers Squibb, she's launched ...

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of $62.00. The company’s shares closed yesterday at ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. Bristol-Myers Squibb beat analysts’ revenue ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...